ClinicalTrials.gg
CompletedNCT01212991PREVAILUpdated Mar 17, 2020Results posted

A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer

A Phase 3 interventional study of Enzalutamide and Placebo in Prostate Cancer, sponsored by Pfizer. Completed at 269 sites in 22 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-03-17.

Sponsored by Pfizer · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,717
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 125 studies testing enzalutamide in Prostatic Neoplasms — 17 open to participants now, 38 under way, 9 of them phase 3. enzalutamide · Prostatic Neoplasms.

Enrollment
2nd of 125
1,717 · median 52
Started
2010
with 2 others
Phase 3
16 of 125
1 open now
Registered
5th of 125
by date
Lead sponsor
12 of 125
Pfizer

Among the 125 studies testing enzalutamide in Prostatic Neoplasms, this one is the 2nd largest by enrollment, is one of 3 that started in 2010, is one of 16 in phase 3, and was the 5th registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

17 of the 125 studies testing enzalutamide in Prostatic Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

12 more — sign in →

By country, each count listing its studies:

All 17 open studies →

About enzalutamide

enzalutamide: first FDA approval 2012 (XTANDI), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 125 studies testing enzalutamide in Prostatic Neoplasms, or all of them as a file.
02

Study summary

The purpose of this study is to determine the benefit of enzalutamide versus placebo as assessed by overall survival and progression-free survival in patients with progressive metastatic prostate cancer who have failed androgen deprivation therapy but not yet received chemotherapy.

03

Conditions studied

  • Prostate Cancer

Browse trials for

Keywords

  • Progressive Metastatic Prostate Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Randomized, Double Blind Treatment Period:

Inclusion criteria

Inclusion Criteria:

  • confirmed adenocarcinoma of the prostate without neuroendocrine differentiation or small cell features
  • Ongoing androgen deprivation therapy with a GnRH analogue or bilateral orchiectomy
  • Progressive disease despite androgen deprivation therapy as defined by rising PSA levels or progressive soft tissue or bony disease
  • No prior treatment with cytotoxic chemotherapy
  • Asymptomatic or mildly symptomatic from prostate cancer

Exclusion criteria

Exclusion Criteria:

  • Severe concurrent disease, infection, or co-morbidity that, in the judgment of the Investigator, would make the patient inappropriate for enrollment
  • Known or suspected or active
  • History of another within the previous 5 years other than curatively treated non-melanomatous skin cancer

Open-Label Treatment Period:

The following inclusion criteria apply to patients receiving enzalutamide or placebo during double-blind treatment.

Eligible patients must meet all inclusion criteria.

  • Received randomized double-blind treatment in PREVAIL;
  • Open-label day 1 visit is within 6 months after this amendment is approved and becomes effective at the study site;
  • Is willing to maintain androgen deprivation therapy with a gonadotropin-releasing hormone (GnRH) agonist/antagonist or has had a bilateral orchiectomy;

The exclusion criteria apply only to patients starting new treatment with enzalutamide after receiving placebo as randomized treatment. Each patient must not meet any of the following criteria:

  • Has taken commercially available enzalutamide (Xtandi);
  • Severe concurrent disease, infection, or co-morbidity that, in the judgment of the Investigator, would make the patient inappropriate for enrollment
  • Known or suspected brain metastasis or active leptomeningeal disease
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
1,717 participants (actual)

Study arms

  • Experimental
    Enzalutamide

    Drug: Enzalutamide

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • Participants received enzalutamide 160 mg, administered as four 40-mg capsules, once per day by mouth. Study drug treatment continued until disease progression (evidence of radiographic progression, a skeletal-related event, or clinical progression) and the initiation of a cytotoxic chemotherapy or an investigational agent, unacceptable toxicity, or withdrawal.

  • DrugPlacebo

    Participants received placebo, administered as four capsules, once per day by mouth. Study drug treatment continued until disease progression (evidence of radiographic progression, a skeletal-related event, or clinical progression) and the initiation of a cytotoxic chemotherapy or an investigational agent, unacceptable toxicity, or withdrawal.

06

What researchers measure

Primary outcomes

  1. Overall Survival

    Overall survival was defined as the time from randomization to death due to any cause. For patients who were alive at the time of the analysis data cutoff, overall survival was censored at the last date the patient was known to be alive or analysis data cutoff date, whichever was first. This included patients who were known to have died after the data analysis cutoff date. Patients with no post-baseline survival information were censored on the date of randomization.

    Time frame: During study period (up to 3 years)

  2. Radiographic Progression-free Survival (rPFS)

    Radiographic progression-free survival was defined as the time from randomization to the first objective evidence of radiographic disease progression assessed by independent central radiology review or death due to any cause within 168 days after treatment discontinuation, whichever was first. Radiographic disease progression was evaluated by CT scan or MRI and radionuclide bone scans at regularly scheduled visits. Radiographic disease progression in bone required a confirmatory scan. Radiographic disease progression in soft tissue did not require a confirmatory scan for purposes of analysis. Radiographic disease progression was evaluated by independent central radiology review using RECIST 1.1 for soft tissue disease and PCWG2 guidelines for bone disease. Patients who did not reach the endpoint were censored at their last assessment.

    Time frame: During study period (up to 20 months)

Secondary outcomes

  1. Time to First Skeletal-related Event

    Time to first skeletal-related event was defined as the time from randomization to the date of the first occurrence of a skeletal-related event for each patient. A skeletal-related event was defined as radiation therapy or surgery to bone for prostate cancer, pathological bone fracture, spinal cord compression, or initiation/change in antineoplastic therapy to treat bone pain from prostate cancer. Skeletal-related events were recorded at each scheduled and unscheduled study visit and during long-term follow-up if a skeletal-related event was not documented previously. Patients who did not have a skeletal-related event at the time of the analysis data cutoff were censored at the date of last assessment indicating no evidence of skeletal-related event. Patients with no postbaseline assessments were censored on the date of randomization.

    Time frame: During study period (up to 3 years)

  2. Time to Initiation of Cytotoxic Chemotherapy

    The time to initiation of cytotoxic chemotherapy is defined as the time from randomization to the date of initiation of cytotoxic chemotherapy for the treatment of prostate cancer for each patient. For patients who did not start cytotoxic chemotherapy at the time of the analysis data cutoff, time to initiation of cytotoxic chemotherapy was censored at the date of last assessment where no cytotoxic chemotherapy was indicated or at the analysis data cutoff date, whichever was first. Time to initiation of cytotoxic chemotherapy for patients with no postbaseline assessments was censored on the date of randomization.

    Time frame: During study period (up to 3 years)

  3. Time to Prostate-specific Antigen (PSA) Progression

    Time to PSA progression was defined as the time from randomization to date of first confirmed observation of PSA progression for each patient. For patients with PSA declines at week 13, the PSA progression date was defined as the date that a ≥ 25% increase and an absolute increase of ≥ 2 ng/mL above the nadir was documented, and confirmed 3 or more weeks later. For patients with no PSA decline at week 13, the PSA progression date was defined as the date that a ≥ 25% increase and an absolute increase of ≥ 2 ng/mL above baseline was documented, and confirmed 3 or more weeks later. For patients who did not have confirmed PSA progression at the time of the analysis data cutoff, time to PSA progression was censored at the date of the last PSA assessment showing no evidence of confirmed PSA progression or the analysis data cutoff date, whichever was first. Time to PSA progression for patients with no postbaseline assessments was censored on the date of randomization.

    Time frame: During study period (up to 3 years)

  4. Percentage of Patients With Prostate Specific Antigen (PSA) Response ≥ 50%

    PSA response was defined as a ≥ 50% reduction in PSA from baseline to the lowest postbaseline PSA value and required confirmation by a consecutive assessment at least 3 weeks later. Patients were evaluable for PSA response rate if a patient had a PSA level measured at baseline and at least one postbaseline assessment.

    Time frame: During study period (up to 3 years)

  5. Best Overall Soft Tissue Response

    The best overall soft tissue objective response is defined as partial response \[PR\] or complete response \[CR\] while on study treatment based on investigator assessments of target, nontarget, and new lesions using RECIST 1.1. Soft tissue was assessed by CT or MRI at regularly scheduled visits. Only patients with measurable soft tissue disease (ie, at least 1 target lesion identified per RECIST 1.1) at screening are included in this analysis. All percentages are based on number of participants with measurable soft tissue disease at screening in each treatment group.

    Time frame: During study period (up to 3 years)

Other outcomes

  1. Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)

    An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent were events between first dose of study drug and up to a maximum of 6.5 years that were absent before treatment or that worsened relative to pretreatment state. AEs included both serious and non-serious AEs.

    Time frame: Baseline to discontinuation from the study or death, whichever occurred first (maximum duration of 6.5 years)

  2. Number of Participants With Treatment-Emergent Adverse Events (AEs) Greater Than or Equal to (>=) Grade 3, Based on National Cancer Institute Common Terminology Criteria for AEs (CTCAE), Version 4.0

    An AE is any untoward medical occurrence in participant who received study drug without regard to possibility of causal relationship. As per NCI CTCAE, Grade 3 events =medically significant but not immediately life-threatening, unacceptable or intolerable events, significantly interrupting usual daily activity, require systemic drug therapy/other treatment, Grade 4 events =participant to be in imminent danger of death. Grade 5 events =death. A treatment-emergent AE (TEAE) was defined as an AE that occurred from the date and time of the first dose of study drug up to a maximum duration of 6.5 years. Number of participants with AEs of any of the Grade 3 or above (Grade 4, 5) were reported.

    Time frame: Baseline to discontinuation from the study or death, whichever occurred first (maximum duration of 6.5 years)

  3. Number of Participants With Treatment-Related Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Treatment-related AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent were events between first dose of study drug and up to a maximum duration of 6.5 years that were absent before treatment or that worsened relative to pre-treatment state. Relatedness to study drug was assessed by the investigator.

    Time frame: Baseline to discontinuation from the study or death, whichever occurred first (maximum duration of 6.5 years)

07

Results

Posted Oct 16, 2014

Participant flow

Double-blind
Participant flow — Double-blind
MilestoneEnzalutamidePlaceboPlacebo Participants Crossover to Enzalutamide
Started8728450
Safety population8718440
Completed02340
Not completed8726110
Withdrew: Lost to follow-up840
Withdrew: Death6995500
Withdrew: Withdrawal by subject16190
Withdrew: Other700
Withdrew: Sponsor decision142380
Open-label
Participant flow — Open-label
MilestoneEnzalutamidePlaceboPlacebo Participants Crossover to Enzalutamide
Started00234
Completed000
Not completed00234
Withdrew: Death00166
Withdrew: Lost to follow-up005
Withdrew: Withdrawal by subject007
Withdrew: Sponsor decision0053
Withdrew: Other003

Outcome measures

PrimaryOverall Survival

Overall survival was defined as the time from randomization to death due to any cause. For patients who were alive at the time of the analysis data cutoff, overall survival was censored at the last date the patient was known to be alive or analysis data cutoff date, whichever was first. This included patients who were known to have died after the data analysis cutoff date. Patients with no post-baseline survival information were censored on the date of randomization.

Time frame:
During study period (up to 3 years)
Reported as:
Median · months
Overall Survival
monthsEnzalutamidePlacebo
Overall Survival32.4 (30.1 to NA)30.2 (28.0 to NA)
Statistical analysis
  • Enzalutamide vs Placebo · Log Rank · p = <0.0001 (A 2-stage group sequential method (Lan DeMets OBF) assigned the level of significance for the pre-specified interim overall survival analysis (p\<0.015) based on overall 2-sided type I error rate of 0.049. Final results based upon interim analysis.) · Hazard ratio (hr): 0.706 · 95% CI 0.596 to 0.837The hazard ratio is based on an unstratified Cox regression model (with treatment as the only covariate) and is relative to placebo with \<1 favoring enzalutamide.
PrimaryRadiographic Progression-free Survival (rPFS)

Radiographic progression-free survival was defined as the time from randomization to the first objective evidence of radiographic disease progression assessed by independent central radiology review or death due to any cause within 168 days after treatment discontinuation, whichever was first. Radiographic disease progression was evaluated by CT scan or MRI and radionuclide bone scans at regularly scheduled visits. Radiographic disease progression in bone required a confirmatory scan. Radiographic disease progression in soft tissue did not require a confirmatory scan for purposes of analysis. Radiographic disease progression was evaluated by independent central radiology review using RECIST 1.1 for soft tissue disease and PCWG2 guidelines for bone disease. Patients who did not reach the endpoint were censored at their last assessment.

Time frame:
During study period (up to 20 months)
Reported as:
Median · months
Radiographic Progression-free Survival (rPFS)
monthsEnzalutamidePlacebo
Radiographic Progression-free Survival (rPFS)NA (13.8 to NA)3.9 (3.7 to 5.4)
Statistical analysis
  • Enzalutamide vs Placebo · Log Rank · p = <0.0001 (The assigned 2-sided type I error rate was 0.001 for the analysis of radiographic progression-free survival.) · Hazard ratio (hr): 0.186 · 95% CI 0.149 to 0.231The hazard ratio is based on an unstratified Cox regression model (with treatment as the only covariate) and is relative to placebo with \< 1 favoring enzalutamide.
SecondaryTime to First Skeletal-related Event

Time to first skeletal-related event was defined as the time from randomization to the date of the first occurrence of a skeletal-related event for each patient. A skeletal-related event was defined as radiation therapy or surgery to bone for prostate cancer, pathological bone fracture, spinal cord compression, or initiation/change in antineoplastic therapy to treat bone pain from prostate cancer. Skeletal-related events were recorded at each scheduled and unscheduled study visit and during long-term follow-up if a skeletal-related event was not documented previously. Patients who did not have a skeletal-related event at the time of the analysis data cutoff were censored at the date of last assessment indicating no evidence of skeletal-related event. Patients with no postbaseline assessments were censored on the date of randomization.

Time frame:
During study period (up to 3 years)
Reported as:
Median · months
Time to First Skeletal-related Event
monthsEnzalutamidePlacebo
Time to First Skeletal-related Event31.1 (29.5 to NA)31.3 (23.9 to NA)
Statistical analysis
  • Enzalutamide vs Placebo · Log Rank · p = <0.0001 (The Holm step down method of multiple comparisons was used to maintain a study wide type I error of 5% for prespecified secondary efficacy analyses. The 2-sided type I error rate was 0.01 for this analysis.) · Hazard ratio (hr): 0.718 · 95% CI 0.610 to 0.844The hazard ratio is based on an unstratified Cox regression model (with treatment as the only covariate) and is relative to placebo with \< 1 favoring enzalutamide.
SecondaryTime to Initiation of Cytotoxic Chemotherapy

The time to initiation of cytotoxic chemotherapy is defined as the time from randomization to the date of initiation of cytotoxic chemotherapy for the treatment of prostate cancer for each patient. For patients who did not start cytotoxic chemotherapy at the time of the analysis data cutoff, time to initiation of cytotoxic chemotherapy was censored at the date of last assessment where no cytotoxic chemotherapy was indicated or at the analysis data cutoff date, whichever was first. Time to initiation of cytotoxic chemotherapy for patients with no postbaseline assessments was censored on the date of randomization.

Time frame:
During study period (up to 3 years)
Reported as:
Median · months
Time to Initiation of Cytotoxic Chemotherapy
monthsEnzalutamidePlacebo
Time to Initiation of Cytotoxic Chemotherapy28.0 (25.8 to NA)10.8 (9.7 to 12.2)
Statistical analysis
  • Enzalutamide vs Placebo · Log Rank · p = <0.0001 (The Holm step down method of multiple comparisons was used to maintain a study wide type I error of 5% for prespecified secondary efficacy analyses. The 2-sided type I error rate was 0.0125 for this analysis.) · Hazard ratio (hr): 0.349 · 95% CI 0.303 to 0.403The hazard ratio is based on an unstratified Cox regression model (with treatment as the only covariate) and is relative to placebo with \< 1 favoring enzalutamide.
SecondaryTime to Prostate-specific Antigen (PSA) Progression

Time to PSA progression was defined as the time from randomization to date of first confirmed observation of PSA progression for each patient. For patients with PSA declines at week 13, the PSA progression date was defined as the date that a ≥ 25% increase and an absolute increase of ≥ 2 ng/mL above the nadir was documented, and confirmed 3 or more weeks later. For patients with no PSA decline at week 13, the PSA progression date was defined as the date that a ≥ 25% increase and an absolute increase of ≥ 2 ng/mL above baseline was documented, and confirmed 3 or more weeks later. For patients who did not have confirmed PSA progression at the time of the analysis data cutoff, time to PSA progression was censored at the date of the last PSA assessment showing no evidence of confirmed PSA progression or the analysis data cutoff date, whichever was first. Time to PSA progression for patients with no postbaseline assessments was censored on the date of randomization.

Time frame:
During study period (up to 3 years)
Reported as:
Median · months
Time to Prostate-specific Antigen (PSA) Progression
monthsEnzalutamidePlacebo
Time to Prostate-specific Antigen (PSA) Progression11.2 (11.1 to 13.7)2.8 (2.8 to 2.9)
Statistical analysis
  • Enzalutamide vs Placebo · Log Rank · p = <0.0001 (The Holm step down method of multiple comparisons was used to maintain a study wide type I error of 5% for prespecified secondary efficacy analyses. The 2-sided type I error rate was 0.0167 for this analysis.) · Hazard ratio (hr): 0.169 · 95% CI 0.147 to 0.195The hazard ratio is based on an unstratified Cox regression model (with treatment as the only covariate) and is relative to placebo with \< 1 favoring enzalutamide.
SecondaryPercentage of Patients With Prostate Specific Antigen (PSA) Response ≥ 50%

PSA response was defined as a ≥ 50% reduction in PSA from baseline to the lowest postbaseline PSA value and required confirmation by a consecutive assessment at least 3 weeks later. Patients were evaluable for PSA response rate if a patient had a PSA level measured at baseline and at least one postbaseline assessment.

Time frame:
During study period (up to 3 years)
Reported as:
Number · Percentage of Participants
Percentage of Patients With Prostate Specific Antigen (PSA) Response ≥ 50%
Percentage of ParticipantsEnzalutamidePlacebo
Percentage of Patients With Prostate Specific Antigen (PSA) Response ≥ 50%78 (75.1 to 80.7)3.5 (2.3 to 5.0)
Statistical analysis
  • Enzalutamide vs Placebo · Cochran-Mantel-Haenszel · p = <0.0001 (The Holm step down method of multiple comparisons was used to maintain a study wide type I error of 5% for prespecified secondary efficacy analyses. The 2-sided type I error rate was 0.025 for this analysis.) · Difference in response rates: 74.51 · 95% CI 71.45 to 77.57
SecondaryBest Overall Soft Tissue Response

The best overall soft tissue objective response is defined as partial response \[PR\] or complete response \[CR\] while on study treatment based on investigator assessments of target, nontarget, and new lesions using RECIST 1.1. Soft tissue was assessed by CT or MRI at regularly scheduled visits. Only patients with measurable soft tissue disease (ie, at least 1 target lesion identified per RECIST 1.1) at screening are included in this analysis. All percentages are based on number of participants with measurable soft tissue disease at screening in each treatment group.

Time frame:
During study period (up to 3 years)
Reported as:
Number · Percentage of participants
Best Overall Soft Tissue Response
Percentage of participantsEnzalutamidePlacebo
Best Overall Soft Tissue Response58.85.0
Statistical analysis
  • Enzalutamide vs Placebo · Cochran-Mantel-Haenszel · p = <0.0001 (The Holm step down method of multiple comparisons was used to maintain a study wide type I error of 5% for prespecified secondary efficacy analyses. The 2-sided type I error rate was 0.05 for this analysis.) · Difference in objective response rate: 53.85 · 95% CI 48.53 to 59.17
Other pre-specifiedNumber of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)

An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent were events between first dose of study drug and up to a maximum of 6.5 years that were absent before treatment or that worsened relative to pretreatment state. AEs included both serious and non-serious AEs.

Time frame:
Baseline to discontinuation from the study or death, whichever occurred first (maximum duration of 6.5 years)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
ParticipantsEnzalutamidePlaceboPlacebo Participants Crossover to Enzalutamide
AEs857791212
SAEs384229104
Other pre-specifiedNumber of Participants With Treatment-Emergent Adverse Events (AEs) Greater Than or Equal to (>=) Grade 3, Based on National Cancer Institute Common Terminology Criteria for AEs (CTCAE), Version 4.0

An AE is any untoward medical occurrence in participant who received study drug without regard to possibility of causal relationship. As per NCI CTCAE, Grade 3 events =medically significant but not immediately life-threatening, unacceptable or intolerable events, significantly interrupting usual daily activity, require systemic drug therapy/other treatment, Grade 4 events =participant to be in imminent danger of death. Grade 5 events =death. A treatment-emergent AE (TEAE) was defined as an AE that occurred from the date and time of the first dose of study drug up to a maximum duration of 6.5 years. Number of participants with AEs of any of the Grade 3 or above (Grade 4, 5) were reported.

Time frame:
Baseline to discontinuation from the study or death, whichever occurred first (maximum duration of 6.5 years)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (AEs) Greater Than or Equal to (>=) Grade 3, Based on National Cancer Institute Common Terminology Criteria for AEs (CTCAE), Version 4.0
ParticipantsEnzalutamidePlaceboPlacebo Participants Crossover to Enzalutamide
Number of Participants With Treatment-Emergent Adverse Events (AEs) Greater Than or Equal to (>=) Grade 3, Based on National Cancer Institute Common Terminology Criteria for AEs (CTCAE), Version 4.0465318129
Other pre-specifiedNumber of Participants With Treatment-Related Adverse Events (AEs) and Serious Adverse Events (SAEs)

Treatment-related AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent were events between first dose of study drug and up to a maximum duration of 6.5 years that were absent before treatment or that worsened relative to pre-treatment state. Relatedness to study drug was assessed by the investigator.

Time frame:
Baseline to discontinuation from the study or death, whichever occurred first (maximum duration of 6.5 years)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Related Adverse Events (AEs) and Serious Adverse Events (SAEs)
ParticipantsEnzalutamidePlaceboPlacebo Participants Crossover to Enzalutamide
AEs579423119
SAEs382214

Adverse events

Collected over Baseline to discontinuation from the study or death, whichever occurred first (maximum duration of 6.5 years). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Enzalutamide699/871 (80.3%)384/871 (44.1%)814/871 (93.5%)
Placebo550/844 (65.2%)229/844 (27.1%)723/844 (85.7%)
Placebo Participants Crossover to Enzalutamide166/234 (70.9%)104/234 (44.4%)180/234 (76.9%)
Most frequent serious events
Showing 10 of 440
Most frequent serious events
EventEnzalutamidePlaceboPlacebo Participants Crossover to Enzalutamide
Disease progressionGeneral disorders10/8717/84411/234
Urinary tract infectionInfections and infestations8/8715/84410/234
Spinal cord compressionNervous system disorders35/87125/84410/234
PneumoniaInfections and infestations14/8717/8448/234
AnaemiaBlood and lymphatic system disorders18/8719/8446/234
General physical health deteriorationGeneral disorders15/87110/8446/234
AstheniaGeneral disorders0/8711/8445/234
Metastatic painNeoplasms benign, malignant and unspecified (incl cysts and polyps)18/87117/8444/234
Pathological FractureMusculoskeletal and connective tissue disorders15/8716/8443/234
UrosepsisInfections and infestations5/8713/8444/234
Most frequent other events
Showing 10 of 34
Most frequent other events
EventEnzalutamidePlaceboPlacebo Participants Crossover to Enzalutamide
FatigueGeneral disorders332/871220/84463/234
Back painMusculoskeletal and connective tissue disorders280/871188/84432/234
ConstipationGastrointestinal disorders220/871145/84438/234
NauseaGastrointestinal disorders211/871192/84434/234
ArthralgiaMusculoskeletal and connective tissue disorders206/871137/84422/234
Decreased appetiteMetabolism and nutrition disorders182/871139/84436/234
DiarrhoeaGastrointestinal disorders160/871121/84420/234
Hot flushVascular disorders159/87166/84411/234
HypertensionVascular disorders148/87136/84428/234
FallInjury, poisoning and procedural complications136/87142/84415/234

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)EnzalutamidePlaceboTotal
<=18 years000
Between 18 and 65 years179179358
>=65 years6936661359
Age, Continuous
Age, Continuous(years)EnzalutamidePlaceboTotal
Mean71.3 ± 8.5171.2 ± 8.4271.3 ± 8.47
Sex: Female, Male
Sex: Female, Male(Participants)EnzalutamidePlaceboTotal
Female000
Male8728451717
Region of Enrollment
Region of Enrollment(count of participants)EnzalutamidePlaceboTotal
United States127120247
Slovakia131427
Finland181533
Spain443781
Lithuania8614
Austria9918
Russian Federation121022
Israel141125
United Kingdom7875153
Italy151530
France8590175
Canada9188179
Poland211839
Belgium282957
Singapore549
Australia116116232
Denmark434487
Netherlands151328
Germany414283
Japan283361
Sweden211839
Korea, Republic of403878
08

Study locations

269 sites
  • University of Alabama at Birmingham
    Birmingham, Alabama 35249, United States
  • University of Alabama at Birmingham
    Birmingham, Alabama 35294, United States
  • The University of Arizona Cancer Center-North Campus
    Tucson, Arizona 85719, United States
  • The University of Arizona Cancer Certer-North Campus
    Tucson, Arizona 85719, United States
  • Cancer Center Oncology Medical Group
    La Mesa, California 91942, United States
  • Keck Hospital of USC
    Los Angeles, California 90033, United States
  • LAC&USC Medical Center
    Los Angeles, California 90033, United States
  • USC/Norris Comprehensive Cancer Center / Investigational Drug Services
    Los Angeles, California 90033, United States
  • USC/Norris Comprehensive Cancer Center
    Los Angeles, California 90033, United States
  • Ronald Reagan UCLA Medical Center Drug Information Center Department of Pharmaceutical Services
    Los Angeles, California 90095, United States
  • UCLA Clark Urology Clinic
    Los Angeles, California 90095, United States
  • North County Oncology Medical Clinic, Inc
    Oceanside, California 92056, United States
  • UC Davis Medical Center
    Sacramento, California 95817, United States
  • University of California Davis Comprehensive Cancer Center
    Sacramento, California 95817, United States
  • Medical Oncology Associates-SD
    San Diego, California 92123, United States
  • Sharp Memorial Hospital Investigational Pharmacy
    San Diego, California 92123, United States
  • Sharp Rees-Stealy
    San Diego, California 92123, United States
  • Stanford University Medical Center
    Stanford, California 94305, United States
  • Anschutz Cancer Center Pavilion Pharmacy
    Aurora, Colorado 80045, United States
  • University of Colorado Hospital, Anschutz Cancer Pavilion
    Aurora, Colorado 80045, United States
  • Lynn Cancer Institute Center for Hematology Oncology
    Boca Raton, Florida 33486, United States
  • Northwestern Medical Faculty Foundation
    Chicago, Illinois 60611, United States
  • Northwestern Memorial Hospital
    Chicago, Illinois 60611, United States
  • Jewish Hospital & St. Mary's Healthcare, Inc.
    Louisville, Kentucky 40245, United States
  • Brigham & Women's Hospital
    Boston, Massachusetts 02115, United States
  • Beth Israel Deaoness Medical Center
    Boston, Massachusetts 02215, United States
  • Dana Farber Cancer Institute
    Boston, Massachusetts 02215, United States
  • Karmanos Cancer Institute
    Detroit, Michigan 48201, United States
  • Karmanos Cancer Institute Weisberg Cancer Treatment Center
    Farmington Hills, Michigan 48334, United States
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
  • Barnes-Jewish West County Hospital
    Creve Coeur, Missouri 63141, United States
  • BJH Pharmacy
    Saint Louis, Missouri 63108, United States
  • Barnes-Jewish Hospital
    Saint Louis, Missouri 63110, United States
  • Washington University School of Medicine
    Saint Louis, Missouri 63110, United States
  • Barnes-Jewish St. Peters Hospital
    Saint Peters, Missouri 63376, United States
  • Nebraska Methodist Hospital
    Omaha, Nebraska 68114, United States
  • The Mount Sinai Medical Center
    New York, New York 10029, United States
  • Memorial Sloan-Kettering Cancer Center
    New York, New York 10065, United States
  • Cancer Centers of North Carolina
    Cary, North Carolina 27518, United States
  • Levine Cancer Institute
    Charlotte, North Carolina 28203, United States
  • Levine Cancer Institute - Main
    Charlotte, North Carolina 28204, United States
  • Levine Cancer Institute - Southpark
    Charlotte, North Carolina 28211, United States
  • Levine Cancer Institute - University
    Charlotte, North Carolina 28262, United States
  • Levine Cancer Institute - Ballantyne
    Charlotte, North Carolina 28277, United States
  • Duke University Medical Center
    Durham, North Carolina 27710, United States
  • Investigational Chemotherapy Services
    Durham, North Carolina 27710, United States
  • Cancer Centers of North Carolina
    Raleigh, North Carolina 27607, United States
  • Portland VA Medical Center Laboratory
    Portland, Oregon 97239, United States
  • Abramson Cancer Center of the University of Pennsylvania at Perelman Center for Advanced Medicine
    Philadelphia, Pennsylvania 19104, United States
  • UPMC Presbyterian
    Pittsburgh, Pennsylvania 15213, United States
  • UPMC Hillman Cancer Center
    Pittsburgh, Pennsylvania 15232, United States
  • Hematology / Oncology MUSC Hollings Cancer Center
    Charleston, South Carolina 29425, United States
  • Medical University of South Carolina - Urology Services
    Charleston, South Carolina 29425, United States
  • MUSC Department of Radiology
    Charleston, South Carolina 29425, United States
  • MUSC Urology Ambulatory Care
    Charleston, South Carolina 29425, United States
  • MUSC Hematology / Oncology Medical Specialty Associates, East Cooper Medical Arts Center 3rd Floor
    Mount Pleasant, South Carolina 29464, United States
  • MUSC Urology Medical Specialty Associates, East Cooper Medical Arts Center 3rd Floor
    Mount Pleasant, South Carolina 29464, United States
  • UT Southwestern Medical Center at Dallas
    Dallas, Texas 75390, United States
  • Virginia Oncology Associates
    Hampton, Virginia 23666, United States
  • Virginia Oncology Associates
    Newport News, Virginia 23606, United States
  • Virginia Oncology Associates
    Norfolk, Virginia 23502, United States
  • Virginia Oncology Associates
    Virginia Beach, Virginia 23456, United States
  • Seattle Cancer Care Alliance
    Seattle, Washington 98109, United States
  • University of Washington Medical Center
    Seattle, Washington 98195, United States
  • University of Wisconsin Hospital and Clinics
    Madison, Wisconsin 53792, United States
  • Concord Repatriation General Hospital
    Concord, New South Wales 2139, Australia
  • St George Private Hospital
    Kogarah, New South Wales 2217, Australia
  • Lismore Base Hospital, Lismore Cancer Care and Haematology Unit
    Lismore, New South Wales 2480, Australia
  • Liverpool Hospital
    Liverpool, New South Wales 2170, Australia
  • North Coast Cancer Institute
    Port Macquarie, New South Wales 2444, Australia
  • Prince of Wales Hospital
    Randwick, New South Wales 2031, Australia
  • Royal North Shore Hospital, Department of Medical Oncology
    St Leonards, New South Wales 2065, Australia
  • Sydney Adventist Hospital
    Sydney, New South Wales 2076, Australia
  • Australian Clinical Trials Pty Ltd
    Wahroonga, New South Wales 2076, Australia
  • SAN Pathology
    Wahroonga, New South Wales 2076, Australia
  • SAN Radiology
    Wahroonga, New South Wales 2076, Australia
  • Calvary Mater Newcastle
    Waratah, New South Wales 2298, Australia
  • Westmead Hospital
    Westmead, New South Wales 2145, Australia
  • Heart Care Partners
    Auchenflower, Queensland 4066, Australia
  • Icon Cancer Care Wesley
    Auchenflower, Queensland 4066, Australia
  • River City Pharmacy
    Auchenflower, Queensland 4066, Australia
  • Icon Cancer Care Chermside
    Chermside, Queensland 4032, Australia
  • University of Queensland Centre for Clinical Research (UQCCR)
    Herston, Queensland 4006, Australia
  • Nuclear Medicine and Imaging Department
    Herston, Queensland 4029, Australia
  • Icon Cancer Care South Brisbane
    South Brisbane, Queensland 4101, Australia
  • Icon Cancer Foundation
    South Brisbane, Queensland 4101, Australia
  • Mater Private Cardiology
    South Brisbane, Queensland 4101, Australia
  • Adelaide Cancer Centre
    Kurralta Park, South Australia 5037, Australia
  • APHS Pharmacy
    Kurralta Park, South Australia 5037, Australia
  • Ashford Cancer Centre Research
    Kurralta park, South Australia 5037, Australia
  • Cancer Care SA Pty Ltd
    Kurralta Park, South Australia 5037, Australia
  • Bendigo Health, Bendigo Hospital
    Bendigo, Victoria 3550, Australia
  • Bendigo Health Medical Imaging
    Bendigo, Victoria 3552, Australia
  • Eastern Health
    Box Hill, Victoria 3128, Australia
  • MIA Box Hill Radiology
    Box Hill, Victoria 3128, Australia
  • Oncology Eastern Clinical Research Unit (ECRU)
    Box Hill, Victoria 3128, Australia
  • Pharmacy Department
    Box Hill, Victoria 3128, Australia
  • Cabrini Hospital Brighton
    Brighton, Victoria 3186, Australia
  • Monash Health Translation Precinct
    Clayton, Victoria 3168, Australia
  • Peter MacCallum Cancer Centre
    East Melbourne, Victoria 3002, Australia

Showing the first 100 of 269 sites across 22 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Cella D, Ganguli A, Turnbull J, Rohay J, Morlock R. US Population Reference Values for Health-Related Quality of Life Questionnaires Based on Demographics of Patients with Prostate Cancer. Adv Ther. 2022 Aug;39(8):3696-3710. doi: 10.1007/s12325-022-02204-3. Epub 2022 Jun 22. PubMed 35731340 ↗
  • Joshua AM, Armstrong A, Crumbaker M, Scher HI, de Bono J, Tombal B, Hussain M, Sternberg CN, Gillessen S, Carles J, Fizazi K, Lin P, Duggan W, Sugg J, Russell D, Beer TM. Statin and metformin use and outcomes in patients with castration-resistant prostate cancer treated with enzalutamide: A meta-analysis of AFFIRM, PREVAIL and PROSPER. Eur J Cancer. 2022 Jul;170:285-295. doi: 10.1016/j.ejca.2022.04.005. Epub 2022 May 26. PubMed 35643841 ↗
  • Tombal BF, Freedland SJ, Armstrong AJ, Beer TM, Stenzl A, Sternberg CN, Hussain M, Ganguli A, Ramaswamy K, Bhadauria H, Ivanescu C, Turnbull J, Holmstrom S, Saad F. Impact of enzalutamide on patient-reported fatigue in patients with prostate cancer: data from the pivotal clinical trials. Prostate Cancer Prostatic Dis. 2022 Feb;25(2):288-295. doi: 10.1038/s41391-021-00447-9. Epub 2021 Sep 13. PubMed 34518652 ↗
  • Armstrong AJ, Lin P, Tombal B, Saad F, Higano CS, Joshua AM, Parli T, Rosbrook B, van Os S, Beer TM. Five-year Survival Prediction and Safety Outcomes with Enzalutamide in Men with Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer from the PREVAIL Trial. Eur Urol. 2020 Sep;78(3):347-357. doi: 10.1016/j.eururo.2020.04.061. Epub 2020 Jun 9. PubMed 32527692 ↗
  • Armstrong AJ, Al-Adhami M, Lin P, Parli T, Sugg J, Steinberg J, Tombal B, Sternberg CN, de Bono J, Scher HI, Beer TM. Association Between New Unconfirmed Bone Lesions and Outcomes in Men With Metastatic Castration-Resistant Prostate Cancer Treated With Enzalutamide: Secondary Analysis of the PREVAIL and AFFIRM Randomized Clinical Trials. JAMA Oncol. 2020 Feb 1;6(2):217-225. doi: 10.1001/jamaoncol.2019.4636. PubMed 31830211 ↗
  • Armstrong AJ, Lin P, Higano CS, Iversen P, Sternberg CN, Tombal B, Phung D, Parli T, Krivoshik A, Beer TM. Prognostic Association of Prostate-specific Antigen Decline with Clinical Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Treated with Enzalutamide in a Randomized Clinical Trial. Eur Urol Oncol. 2019 Nov;2(6):677-684. doi: 10.1016/j.euo.2018.11.005. Epub 2018 Dec 3. PubMed 31274110 ↗
  • Armstrong AJ, Lin P, Higano CS, Sternberg CN, Sonpavde G, Tombal B, Templeton AJ, Fizazi K, Phung D, Wong EK, Krivoshik A, Beer TM. Development and validation of a prognostic model for overall survival in chemotherapy-naive men with metastatic castration-resistant prostate cancer. Ann Oncol. 2018 Nov 1;29(11):2200-2207. doi: 10.1093/annonc/mdy406. PubMed 30202945 ↗
  • Rathkopf DE, Beer TM, Loriot Y, Higano CS, Armstrong AJ, Sternberg CN, de Bono JS, Tombal B, Parli T, Bhattacharya S, Phung D, Krivoshik A, Scher HI, Morris MJ. Radiographic Progression-Free Survival as a Clinically Meaningful End Point in Metastatic Castration-Resistant Prostate Cancer: The PREVAIL Randomized Clinical Trial. JAMA Oncol. 2018 May 1;4(5):694-701. doi: 10.1001/jamaoncol.2017.5808. PubMed 29522174 ↗
  • Kim CS, Choi YD, Lee SE, Lee HM, Ueda T, Yonese J, Fukagai T, Chiong E, Lau W, Abhyankar S, Theeuwes A, Tombal B, Beer TM, Kimura G. Post hoc analyses of East Asian patients from the randomized placebo-controlled PREVAIL trial of enzalutamide in patients with chemotherapy-naive, metastatic castration-resistant prostate cancer. Medicine (Baltimore). 2017 Jul;96(27):e7223. doi: 10.1097/MD.0000000000007223. PubMed 28682871 ↗
  • Devlin N, Herdman M, Pavesi M, Phung D, Naidoo S, Beer TM, Tombal B, Loriot Y, Ivanescu C, Parli T, Balk M, Holmstrom S. Health-related quality of life effects of enzalutamide in patients with metastatic castration-resistant prostate cancer: an in-depth post hoc analysis of EQ-5D data from the PREVAIL trial. Health Qual Life Outcomes. 2017 Jun 23;15(1):130. doi: 10.1186/s12955-017-0704-y. PubMed 28645287 ↗
  • Bryce AH, Alumkal JJ, Armstrong A, Higano CS, Iversen P, Sternberg CN, Rathkopf D, Loriot Y, de Bono J, Tombal B, Abhyankar S, Lin P, Krivoshik A, Phung D, Beer TM. Radiographic progression with nonrising PSA in metastatic castration-resistant prostate cancer: post hoc analysis of PREVAIL. Prostate Cancer Prostatic Dis. 2017 Jun;20(2):221-227. doi: 10.1038/pcan.2016.71. Epub 2017 Jan 24. PubMed 28117385 ↗
  • Beer TM, Armstrong AJ, Rathkopf D, Loriot Y, Sternberg CN, Higano CS, Iversen P, Evans CP, Kim CS, Kimura G, Miller K, Saad F, Bjartell AS, Borre M, Mulders P, Tammela TL, Parli T, Sari S, van Os S, Theeuwes A, Tombal B. Enzalutamide in Men with Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study. Eur Urol. 2017 Feb;71(2):151-154. doi: 10.1016/j.eururo.2016.07.032. Epub 2016 Jul 28. PubMed 27477525 ↗
  • Kim CS, Theeuwes A, Kwon DD, Choi YD, Chung BH, Lee HM, Lee KH, Lee SE. The PREVAIL trial of enzalutamide in men with chemotherapy-naive, metastatic castration-resistant prostate cancer: Post hoc analysis of Korean patients. Investig Clin Urol. 2016 May;57(3):174-83. doi: 10.4111/icu.2016.57.3.174. Epub 2016 May 10. PubMed 27195316 ↗
  • Graff JN, Baciarello G, Armstrong AJ, Higano CS, Iversen P, Flaig TW, Forer D, Parli T, Phung D, Tombal B, Beer TM, Sternberg CN. Efficacy and safety of enzalutamide in patients 75 years or older with chemotherapy-naive metastatic castration-resistant prostate cancer: results from PREVAIL. Ann Oncol. 2016 Feb;27(2):286-94. doi: 10.1093/annonc/mdv542. Epub 2015 Nov 16. PubMed 26578735 ↗
  • Loriot Y, Miller K, Sternberg CN, Fizazi K, De Bono JS, Chowdhury S, Higano CS, Noonberg S, Holmstrom S, Mansbach H, Perabo FG, Phung D, Ivanescu C, Skaltsa K, Beer TM, Tombal B. Effect of enzalutamide on health-related quality of life, pain, and skeletal-related events in asymptomatic and minimally symptomatic, chemotherapy-naive patients with metastatic castration-resistant prostate cancer (PREVAIL): results from a randomised, phase 3 trial. Lancet Oncol. 2015 May;16(5):509-21. doi: 10.1016/S1470-2045(15)70113-0. Epub 2015 Apr 14. PubMed 25888263 ↗
  • Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, Iversen P, Bhattacharya S, Carles J, Chowdhury S, Davis ID, de Bono JS, Evans CP, Fizazi K, Joshua AM, Kim CS, Kimura G, Mainwaring P, Mansbach H, Miller K, Noonberg SB, Perabo F, Phung D, Saad F, Scher HI, Taplin ME, Venner PM, Tombal B; PREVAIL Investigators. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014 Jul 31;371(5):424-33. doi: 10.1056/NEJMoa1405095. Epub 2014 Jun 1. PubMed 24881730 ↗

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2010 to primary completion in Sep 2013, 36 months.

Results were first posted in Oct 2014, 1 year after primary completion.

Of 126 industry-sponsored phase 3 interventional studies under Prostatic Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 53. This study's 36 months is close to that.

Counting every sponsor, half of 265 studies reached it within 57 months; a quarter within 31 and three quarters within 100.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 29, 2010
First posted
Oct 1, 2010
StartActual
Sep 16, 2010
Primary completionActual
Sep 30, 2013
CompletionActual
Feb 14, 2019
Results first posted
Oct 16, 2014
Last update
Mar 17, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 17, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01212991
Lead sponsor
Pfizer
Collaborators
Astellas Pharma Inc, Medivation LLC, a wholly owned subsidiary of Pfizer Inc.
Responsible party
Sponsor
First posted
Oct 1, 2010
Start date
Sep 16, 2010
Primary completion
Sep 30, 2013
Completion
Feb 14, 2019
Results posted
Oct 16, 2014
Last update
Mar 17, 2020

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Enzalutamide

Start the discussion